FKBP4 and glioblastoma: Recent research on glioma showed, that inhibition of FKBP51 decreased the PD-L1 levels (Programmed Death Ligand 1) in glioma cells, suggesting FKBP51 as a potential target of immunomodulatory strategies for glioblastoma treatment (D'Arrigo et al., 2017).